Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Published on :

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting two posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held in New Orleans, Louisiana, from April 8-13. The posters to be presented at AACR are developed from the investigational nucleic acid platform, UNITE™ (UNiversal Intracellular Targeted Expression) for two vaccines, ITI-3000 for Merkel cell carcinoma and Her2/Neu-LAMP DNA vaccine, both which fuse a tumor associated antigen with lysosomal associated membrane protein 1 (LAMP-1). This proprietary lysosomal targeting technology results in enhanced antigen presentation and a balanced T cell response.

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

Published on :

Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate

Six Biotechs to Watch in 2021

Published on :

2020 was an interesting year for the biotech industry and the BioHealth Capital Region as we adjusted to continue moving forward during the COVID-19 Pandemic. While the biggest stories in terms of dollars were related to the Coronavirus and funding to create a vaccine in record time, that didn’t stop other biotech companies from working hard to develop their research, science, and/or devices.

2020’s Top 10 Most Read News Stories from the BioHealth Capital Region

Published on :

2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.

End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region

Published on :

This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.

10 International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health

Published on :

The state of Maryland is the global epicenter of vaccine research and development. This has never been more evident than right now as scores of Maryland companies have risen to the global challenge of developing the first approved vaccine for SARS-CoV-2.

2020 Life Science Venture Capital Funding Roundup for Q1/Q2 in the BioHealth Capital Region

Published on :

2020 Life Science Venture Capital Funding Roundup for Q1/Q2 in the BioHealth Capital Region  BioHealth Companies raised more than $178M in the first half of 2020 June 9, 2020 This [….]

Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO

William Hearl - CEO, Chairman of the Board, and Founder of Immunic Therapeutics
Published on :

Maryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO Immunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising [….]